Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the BIO CEO and Investor Conference

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
February 12, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b...
February 07, 2024 08:30 ET | Source: CervoMed Inc.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating...
February 05, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the Emerging Growth Conference 67

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
January 05, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the Emerging Growth Conference 66

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
August 15, 2023 16:01 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 ...
March 30, 2023 07:00 ET | Source: Diffusion Pharmaceuticals Inc.

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in...
December 16, 2022 06:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be...
December 05, 2022 06:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies...
November 14, 2022 16:01 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities...